Skip to Main Content

Fibrogen (FGEN) “believes” that its experimental anemia pill is safe. That’s nice, but on Thursday night, the San Francisco-based drug maker refused to disclose the actual data generated by a comprehensive examination of cardiac safety in thousands of patients enrolled in its clinical trials.

The safety data remain obscured, so Fibrogen’s wobbly assurances about the heart safety of its anemia pill are raising more questions than were answered.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED